Literature DB >> 12729390

Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Sylvie Retout1, France Mentré.   

Abstract

We extend the development of the expression of the Fisher information matrix in nonlinear mixed effects models for designs evaluation. We consider the dependence of the marginal variance of the observations with the mean parameters and assume an heteroscedastic variance error model. Complex models with interoccasions variability and parameters quantifying the influence of covariates are introduced. Two methods using a Taylor expansion of the model around the expectation of the random effects or a simulated value, using then Monte Carlo integration, are proposed and compared. Relevance of the resulting standard errors is investigated in a simulation study with NONMEM.

Mesh:

Year:  2003        PMID: 12729390     DOI: 10.1081/BIP-120019267

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  31 in total

1.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

2.  Serial correlation in optimal design for nonlinear mixed effects models.

Authors:  Joakim Nyberg; Richard Höglund; Martin Bergstrand; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-14       Impact factor: 2.745

3.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

Review 4.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

5.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

Review 6.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 7.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

8.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

9.  Optimal design for multivariate response pharmacokinetic models.

Authors:  Ivelina Gueorguieva; Leon Aarons; Kayode Ogungbenro; Karin M Jorga; Trudy Rodgers; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-21       Impact factor: 2.745

10.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.